Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

HHSC to Implement Clinical Prior Authorization for Antimigraine Agents – Ergot Derivatives on June 6, 2023

Last updated on

On June 6, 2023, the Texas Health and Human Services Commission (HHSC) will implement clinical prior authorization for antimigraine agents – ergot derivatives. The Texas Drug Utilization Review Board approved these clinical prior authorizations on April 28, 2023.

These clinical prior authorizations are optional for managed care organizations (MCOs).

The Pharmacy Clinical Prior Authorization Assistance Chart shows each MCO's prior authorizations and how these authorizations relate to those that are used for processing fee-for-service Medicaid claims. This chart is updated quarterly. Providers can refer to the MCO Resources page for links to each MCO's list of clinical prior authorizations.

Email with comments or questions.